Acquisitions and Investments - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended								8 Months Ended	12 Months Ended
	May 09, 2022	Apr. 29, 2022	Sep. 14, 2021	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Fair value of shares included in consideration from GeneDx Holdings													$ 172,000	$ 0	$ 0
Total assets of equity method investees				$ 2,167,259				$ 2,399,715				$ 2,167,259	2,167,259	2,399,715
Total liabilities of equity method investees				605,611				714,589				605,611	605,611	714,589
Market value				1,300				4,500				$ 1,300	1,300	4,500
Total revenues				$ 185,340	$ 179,744	$ 309,893	$ 329,219	401,332	$ 385,813	$ 442,408	$ 545,165		1,004,196	1,774,718	1,435,413
Transfer Of Intellectual Property And Other [Member]
Business Acquisition [Line Items]
Total revenues													$ 105,721	25,842	$ 53,219
LeaderMed | LenderMed Joint Venture | Corporate Joint Venture
Business Acquisition [Line Items]
Joint venture (in shares)			4,703
Ownership interest in joint venture (as a percent)			47.00%
LeaderMed | LenderMed Joint Venture | Corporate Joint Venture | Transfer Of Intellectual Property And Other [Member]
Business Acquisition [Line Items]
Total revenues			$ 1,000											1,000
GeneDx Holdings | Common Class A
Business Acquisition [Line Items]
Investment owned (in shares)				80,000,000								80,000,000	80,000,000
Equity Method Investment, Nonconsolidated Investee or Group of Investees
Business Acquisition [Line Items]
Total assets of equity method investees				$ 167,100				223,600				$ 167,100	$ 167,100	223,600
Total liabilities of equity method investees				$ 46,500				$ 37,900				$ 46,500	46,500	37,900
Net losses of equity method investees													$ 101,500	$ 69,400
Pharmsynthez
Business Acquisition [Line Items]
Equity method investments (as a percent)				9.00%								9.00%	9.00%
Cocrystal Pharma
Business Acquisition [Line Items]
Equity method investments (as a percent)				3.00%								3.00%	3.00%
NIMS
Business Acquisition [Line Items]
Equity security investments (as a percent)				1.00%								1.00%	1.00%
Neovasc
Business Acquisition [Line Items]
Equity method investments (as a percent)				0.00%								0.00%	0.00%
BioCardia, Inc.
Business Acquisition [Line Items]
Equity method investments (as a percent)				1.00%								1.00%	1.00%
Number of shares into which warrants may be converted (in shares)				47,000				47,000				47,000	47,000	47,000
Xenetic Biosciences, Inc.
Business Acquisition [Line Items]
Equity method investments (as a percent)				3.00%								3.00%	3.00%
LeaderMed
Business Acquisition [Line Items]
Stock ownership (as a percent)													47.00%
Phio Pharmaceuticals
Business Acquisition [Line Items]
Equity security investments (as a percent)				0.01%								0.01%	0.01%
VBI Vaccines Inc
Business Acquisition [Line Items]
Equity security investments (as a percent)				1.00%								1.00%	1.00%
ChromaDex Corporation
Business Acquisition [Line Items]
Equity security investments (as a percent)				0.10%								0.10%	0.10%
Eloxx Pharmaceuticals
Business Acquisition [Line Items]
Equity security investments (as a percent)				1.00%								1.00%	1.00%
CAMP4
Business Acquisition [Line Items]
Equity security investments (as a percent)				2.00%								2.00%	2.00%
HealthSnap
Business Acquisition [Line Items]
Equity security investments (as a percent)				7.00%								7.00%	7.00%
Cocrystal
Business Acquisition [Line Items]
Number of shares into which warrants may be converted (in shares)				33,000				33,000				33,000	33,000	33,000
InCellDx Inc.
Business Acquisition [Line Items]
Number of shares into which warrants may be converted (in shares)				700,000				700,000				700,000	700,000	700,000
Zebra
Business Acquisition [Line Items]
Stock ownership (as a percent)													29.00%
Zebra | Variable Interest Entity, Not Primary Beneficiary
Business Acquisition [Line Items]
Equity method investments (as a percent)				29.00%				29.00%				29.00%	29.00%	29.00%
Zebra | Series A Preferred Stock | Variable Interest Entity, Not Primary Beneficiary
Business Acquisition [Line Items]
Investment owned (in shares)				1,260,000								1,260,000	1,260,000
Zebra | Restricted Stock | Variable Interest Entity, Not Primary Beneficiary
Business Acquisition [Line Items]
Shares received as a gift (in shares)													900,000
GeneDx Holdings
Business Acquisition [Line Items]
Stock ownership (as a percent)													21.00%
Market value				$ 21,100								$ 21,100	$ 21,100
Net losses for fair value changes in investment													$ 150,900
GeneDx Holdings | GeneDx Holdings
Business Acquisition [Line Items]
Equity method investments (as a percent)				21.00%								21.00%	21.00%
Equity securities
Business Acquisition [Line Items]
Stock price (in dollars per share)	$ 2.44
ModeX
Business Acquisition [Line Items]
Total aggregate consideration	$ 300,000
Total purchase price	221,662
Vested equity awards	2,300
Net loss												$ 10,600
ModeX | Equity securities
Business Acquisition [Line Items]
Fair value of shares included in consideration from GeneDx Holdings	$ 219,400
Stock price (in dollars per share)	$ 2.44
Detect Genomix | GeneDx Holdings
Business Acquisition [Line Items]
Total aggregate consideration		$ 447,000
Payments to acquire business		$ 150,000
Outstanding shares held (as a percent)		5.00%